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Abstract
Background: Malignant pleural mesothelioma is considered an almost incurable tumour with increasing incidence
worldwide. It usually develops in the parietal pleura, from mesothelial lining or submesothelial cells, subsequently invading
the visceral pleura. Chromosomal and genomic aberrations of mesothelioma are diverse and heterogenous. Genome-wide
profiling of mesothelioma versus parietal and visceral normal pleural tissue could thus reveal novel genes and pathways
explaining its aggressive phenotype.
Methodology and Principal Findings: Well-characterised tissue from five mesothelioma patients and normal parietal and
visceral pleural samples from six non-cancer patients were profiled by Affymetrix oligoarray of 38 500 genes. The lists of
differentially expressed genes tested for overrepresentation in KEGG PATHWAYS (Kyoto Encyclopedia of Genes and
Genomes) and GO (gene ontology) terms revealed large differences of expression between visceral and parietal pleura, and
both tissues differed from mesothelioma. Cell growth and intrinsic resistance in tumour versus parietal pleura was reflected
in highly overexpressed cell cycle, mitosis, replication, DNA repair and anti-apoptosis genes. Several genes of the ‘‘salvage
pathway’’ that recycle nucleobases were overexpressed, among them TYMS, encoding thymidylate synthase, the main
target of the antifolate drug pemetrexed that is active in mesothelioma. Circadian rhythm genes were expressed in favour of
tumour growth. The local invasive, non-metastatic phenotype of mesothelioma, could partly be due to overexpression of
the known metastasis suppressors NME1 and NME2. Down-regulation of several tumour suppressor genes could contribute
to mesothelioma progression. Genes involved in cell communication were down-regulated, indicating that mesothelioma
may shield itself from the immune system. Similarly, in non-cancer parietal versus visceral pleura signal transduction, soluble
transporter and adhesion genes were down-regulated. This could represent a genetical platform of the parietal pleura
propensity to develop mesothelioma.
Conclusions: Genome-wide microarray approach using complex human tissue samples revealed novel expression patterns,
reflecting some important features of mesothelioma biology that should be further explored.
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Introduction
Malignant mesothelioma is an aggressive and incurable tumour
with currently a median survival of 12months[1]. Its inherent chemo-
and radio-resistance has spread treatment nihilism over four
decades[2]. Occasionally however, good responders and long-term
survivors are seen. Mesothelioma is derived from cells of the pleura,
peritoneum or tunica vaginalis, of which pleural location accounts for
about 70% of the cases[3]. Epithelial subtype is the most common,
and is an important positive prognostic factor in contrast to the
sarcomatous and mixed subtypes. Mesothelioma predilection site is
the parietal pleura (Fig. 1) where tumour grows in a loco-regional
pattern, spreading to the visceral pleura and invade the surrounding
structures[4]. Asbestos is the most important carcinogenic factor, but
radiation can induce it and Simian virus 40 (SV40) has been
implicated, but mainly as a co-factor[1]. Asbestos fibres are found
both in the parietal and visceral pleura as well as in the lung. Why the
parietal pleura and not the visceral pleura is the main target organ of
mesothelioma is unknown, so a higher grade of susceptibility to
oncogenic factors than the visceral pleura could be hypothesized.
Moreover cytogenetic studies have shown that mesotheliomas
have highly complex and variable chromosomal aberrations[5],
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and only few common important features have been identified, as
the deletion of 9p21 including the CDKN2A gene[6]. Conse-
quently genome-wide microarray analysis may be a more fruitful
method to identify the most important common and crucial genes
and pathways involved in its biology. Genome-wide studies of
pleural mesothelioma versus normal non-cancer parietal and
visceral pleura have yet to be published. The main aim of this
study was to analyze the gene profile of human pleural
mesothelioma versus normal parietal and visceral pleural tissues,
focusing on pathway analysis and differential gene expression
correlated to gene function.
Results
Characterization of the patients and tissues
Gene expression analysis of six mesothelioma samples where
two were from the same patient, seven parietal pleural samples
where two were from the same patient and three visceral pleural
samples were accomplished (Table 1). Mean age of controls was 27
years and of cases 56 years. None of the controls were reportedly
ever exposed to asbestos, whereas four of five cases had various
levels of exposure. Parietal pleura samples from the controls had
normal histology, except case 2 that had partly reactive fibrosis
(Table 2). The visceral pleural samples, that were from the same
control patients were part of, or close to a bullae, described as
bullous emphysema by histological examination, but none of the
patients had an ephysema diagnosis nor clinical emphysema. By
light microscopy of Hematoxylin-Eosin-Safranin-staining of nor-
mal tissue and diagnostic immunohistochemistry of the tumour
samples we identified 17 cell-types (not shown), where four cell
types mainly distinguished tumour from normal pleura. These
were mesothelioma cells that were in abundance in the tumour
samples, normal mesothelial, endothelial cells and fibrocytes in the
normal pleura (Table 3). Larger vessels were more frequent in the
parietal samples than the visceral. The visceral vessels were
surrounded by leuko- and histiocytes, and in two of the visceral
samples 30% of the cells were alveolar. Collagen was abundant in
both visceral and parietal pleura.
General expression characteristics
PCA (principal component analysis) and a PLS (bridge-partial
least squares regression) model showed that mesothelioma, parietal
Figure 1. Schematic presentation of mesothelioma, the parietal and visceral pleura. Representative histology showing the most abundant
cell types.
doi:10.1371/journal.pone.0006554.g001
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and visceral pleural tissues had distinct differential gene expression
profiles[7]. Importantly there was higher inter-individual than intra-
individual gene expression similarity between parietal and visceral
pleura and there were more down-regulated than overexpressed
genes in mesothelioma versus normal tissues ([7] and Fig. 2). KEGG
PATHWAY analysis comparing the distribution of the gene
expression of each pathway visualised in a graphic model, showed
among others that the purine and pyrimidine metabolic pathways
(not shown), cell cycle and proteasome, were selectively overex-
pressed in tumour (Fig. 3). Cytokine-cytokine receptor interaction,
Table 1. Description of cases (T) and controls (C).
ID Cases Age Gender Survival History
Primary
stage
Asbestos exposure
years (y)
Smoking
years (y)
1 C 25 M Recurrent right-sided pneumothorax, apical and
lateral right superior lobe bullae.
T0N0M0 0 4
2 C 16 F Recurrent left-sided pneumothorax, apical bullae. T0N0M0 0 0
3 C 27 M Recurrent right-sided pneumothorax, apical bullae. T0N0M0 0 12
4 C 51 M Recurrent right-sided pneumothorax, multiple cysts
superior lobe.
T0N0M0 0 34
5 C 19 M Recurrent right-sided pneumothorax, apical bullae T0N0M0 0 1
6 C 18 M Left- then right-sided pneumothorax, apical bullae. T0N0M0 0 0
7 T 58 M 15 Thoracic pain 6 months, then dyspnoea and
expectorate, 6xCCG with partial remission, progression
after 4xPC.
T2N2M1 Unsure, possible
ecological
30
8 T 42 F 69 Dyspnoea 8 months, tumor in mediastinum, 6xCCG
with partial remission, now 36xPC with excellent partial
remission.
T4N3M0 Hair-dryer with asbestos
elements, 9
6
9 T 71 M 11 Pain right thorax and dyspnoea 4 months, 5 kg
weight loss, 2xpegylated doxorubicin, progression,
4xPC with stable disease
T2N2M0 Minimal Not
answered
10 T 50 F 6 Large tumour of right thorax involving the breast
and mediastinum, radiotherapy 3Gy x 13 because of
vena cava superior syndrome, no effect, new biopsy 1
month later, 1xCCG with haematological toxicity grade
IV. No more treatment indicated.
T4N3M1 Unsure, worked in canning
industry, old building
35
11 T 64 M 17 15 months breathless, weight loss 20 kg, blood-tinged
pleural fluid, no pathological cells in pleural fluid after 3
months, tumour left pleura. 3xPC with progression,
6xCCG with clinical effect.
T2N1MX 40 35
PC=pemetrexed and carboplatin, CCG=pegylated doxorubicin, carboplatin and gemcitabine.
Survival was calculated in months from diagnosis (m).
doi:10.1371/journal.pone.0006554.t001
Table 2. RNA isolation and histopathology.
ID RNA Histology P:positive, N:negative
1 PP two samples Visceral pleura: Bullous emphysema*. Parietal pleura: Normal
2 PP and PV Visceral pleura: Bullous emphysema. Parietal pleura: Reactive fibrosis and normal
3 PP Visceral pleura: Bullous emphysema. Parietal pleura: ND
4 PP and PV Visceral pleura: Bullous emphysema fibrous thickening. Parietal pleura: Normal
5 PP and PV Visceral pleura: Bullous emphysema. Parietal pleura: Normal
6 PP Visceral pleura: Emphysematous bullae. Parietal pleura: Normal
7 T Epithelial type. P: Calretinin, EMA some positive cells, CK5/6. N: CEA, BerEp4, PSA,
8 T Epithelial type. P: Calretinin, EMA moderate, CK 7. N: CEA, BerEp4, S-100, Chromogranin, Thyreoglobulin, Calcitonin, TTF-
1, Synaptophysine, CK20
9 T Epithelial type P: Calretinin, EMA, Pancytokeratin, CK5/6, Vimentin,MIB1 30%. N: CEA, BerEp4
10 T from two locations Epithelial type, grade 3. P: Calretinin, EMA, BerEp4 (focal), Pancytokeratin, N: CEA, CK20, Estrogen, Progesterone, Erbb2
11 T Biphasic type P: Calretinin- small groups, EMA, CK7 focal, CK5/6 some positive cells, Vimentin, BerEp4-focal. N: CEA, CK20,
TTF-1, PSA, PSF
RNA was isolated from parietal pleura (PP) visceral pleura (PV) and mesothelioma (T).
*Controls were operated for spontaneous pneumothorax. Histology of the bullae that induced the pneumothorax showed that none had clinical or radiological
emphysema.
doi:10.1371/journal.pone.0006554.t002
Mesothelioma Gene Profile
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6554
leukocyte transendothelial migration and apoptosis were mainly
down-regulated in tumour (Fig. 3).
Parietal versus visceral pleura
There were 392 differentially expressed genes between the
normal parietal and visceral pleura, where 341 genes were down-
regulated and only 52 genes overexpressed in parietal pleura (Fig. 2).
No gene ontology (GO) entities were overexpressed in parietal
pleura but several entities were down-regulated compared to
visceral pleura (Table 4). Among the most important were the
genes intrinsic to membrane, signal transduction and adhesion
genes. Single genes reflecting this was down-regulation of integrins
(ITGA2, ITGB3, ITGA8), claudins (CLDN4, CLDN7), protein
kinases (PRKCE, PRKCZ) and syndecan 1 (SDC1). In KEGG
PATHWAYS focal adhesion and leukocyte endothelial migration
was also down-regulated.
Mesothelioma versus parietal pleura
Since the parietal pleura is the predilection site for mesotheli-
oma, we further compared the mRNA expression of mesothelioma
with normal parietal pleura. There were 828 overexpressed and
1004 down-regulated genes in tumour tissue (Fig. 2). Of these, 75
and 75 respectively, had no Unigene annotation, nor a gene
symbol. GO entities involved in important biological functions
including cell cycle, DNA repair and microtubule cytoskeleton
genes were highly overexpressed (Table 5 and [7]).
Down-regulated GO entities were related to multicellular
organism development and cell communication, defense, cell
adhesion and interestingly, several circadian rhythm genes
(Table 6). Moreover important tumor suppressor genes as DLC1
(deleted in liver cancer 1), TNF (tumour necrosis factor), CAV1
(caveolin-1) and GSN (gelsolin) were down-regulated. Contrary to
other cancers, the well-known anti-apoptotic BCL2, the FOS
Table 3. Cell types fraction of nucleated cells in parietal pleura (PP) and tumour (T).
% of nucleated cells in each biopsy
ID
Epith. Comp
mesothelioma
Sarc. Comp
Mesothelioma Mesothelium Endothelium Fibrocytes Lymphocytes
1 PP 0 0 10 40 40 2
2 PP 0 0 1 30 50 2
3 PP ND ND ND ND ND ND
4 PP 0 0 1 20 50 1
5 PP 0 0 5 20 15 24
6 PP 0 0 15 40 20 10
7 T 55 0 ,1 2 4 25
8 T 90 0 0 1 5 2
9 T 90 0 0 3 1 2
10 T 90 0 0 ,1 3 2
11 T 25 15 ,1 5 10 15
One of the two samples of case no. 10 is removed as non-representative histologically (see text). ND= not done.
doi:10.1371/journal.pone.0006554.t003
Figure 2. Venn diagram of significantly up- and down-regulated genes (n) in mesothelioma (T) versus normal parietal pleura (pp)
and normal visceral pleura (pv) (P,0.05). 828 genes are overexpressed (red) and 1004 genes are down-regulated (green) in T versus pp. 341
genes are overexpressed (blue) and 52 genes downregulated (brown) in pv versus pp.
doi:10.1371/journal.pone.0006554.g002
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oncogene and the multidrug resistance gene ABCB1 (ATP-binding
cassette sub-family B member 1) were down-regulated.
Verification of protein expression
All samples of tissue adjacent to the tissue subjected to
microarray, except control no. 3 where analysed by immunohis-
tochemistry for protein expression of six selected genes. Due to
limited biological material (needle biopsies) we had to be very
selective in chosing which genes to verify. Overexpression was
verified for Thymidylate Synthase, VG5Q, Chk1, NQO1 and
RAD21, where tumour cells were positive in most cases. Normal
mesothelial cells, that was a minor population of the biopsies
(Table 3) stained positive for NQO1 and VG5Q, weakly for
RAD21. MSLN (Mesothelin) mRNA was not differentially
Figure 3. Selected pathways with distribution of differentially expressed genes (P,0.05). This graph depicts the areas of differentially
expressed genes in tumour (T), parietal pleura (PP) and visceral pleura (PV). Each dot represents a gene, where red represent genes overexpressed in
tumour and green represent genes overexpressed in parietal pleura or visceral pleura. Gray represents all the genes of the chip and yellow represents
the genes non-differentially expressed in each pathway. Genes associated to the cell cycle and the proteasome are uniformly overexpressed. More
genes associated to apoptosis are downregulated than overexpressed and most genes involved in cytokine-cytokine receptor interaction are down-
regulated. Important circadian rhythm genes are differentially regulated (see Fig. 8).
doi:10.1371/journal.pone.0006554.g003
Table 4. A selection of down-regulated gene ontology (GO) entities and genes (Down Genes) in normal parietal pleura versus
visceral pleural tissue.
GO terms Down Genes Genes on Chip Corrected P-values
GO:0031224 intrinsic to membrane 105 4176 1,18E-05
GO:0050828 regulation of liquid surface tension 4 5 0,0014
GO:0007275 multicellular organismal development 51 1984 0,0033
GO:0004871 signal transducer activity 43 1797 0,0344
GO:0007155 cell adhesion 21 664 0,0425
GO:0045893 positive regulation of transcription, DNA-dependent 11 201 0,0287
GO:0006814 sodium ion transport 8 108 0,0317
Genes on Chip = the number of genes from each entity represented on the gene chip.
doi:10.1371/journal.pone.0006554.t004
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expressed, despite its strong protein expression in mesothelio-
mas[8]. Mesothelin protein was highly expressed in both
mesothelial and stromal cells of the control samples, that could
explain the non-differential expression of MSLN mRNA.
Histological pictures of normal parietal samples and biphasic
mesothelioma stained with VG5Q, Thymidylate Synthase, and
Mesothelin antibodies are shown illustrating the expression in
normal pleura and the malignant epithelial and sarcomatous
components (Fig. 4).
Discussion
Genome-wide profiling of malignant pleural mesothelioma versus
normal parietal pleura showed several new and interesting
expression patterns highly relevant to the biology of mesothelioma.
The gene expression differences between the parietal and visceral
pleural tissues described here for the first time were significant and
may be important for understanding the parietal pleura propensity
for developing mesothelioma. Many of those features have been
recognised mainly in epithelial malignant tumours, as will be
discussed below, thus showing important genotypic similarities
between this tumour of probably mesodermal origin and epithelial
cancers. Moreover, 150 differentially expressed genes without known
function were identified that may gain importance in the future.
When interpreting gene expression data one must also keep in
mind that they represent relative values, so that overexpression e.g.
in tumour also could reflect down-regulation in the normal tissue.
Parietal versus visceral pleura
There were significant expression differences between these two
pleural membranes. Interestingly the expression of the visceral
Table 5. A selection of overexpressed gene ontology (GO) entities with corresponding genes (Genes Up) in mesothelioma versus
parietal pleura.
GO term Genes Up Genes on Chip Corrected P-value Gene Symbols
GO:0007049 cell cycle 82 802 1,33E-15
GO:0006260 DNA replication 27 181 3,51E-08 PHB,PCNA,TOP2A,RRM1,MCM3,MCM6,
CDK2AP1,MCM2,TYMS,SSBP1,MSH6,
RNASEH2A,RFC5,CDC6,RFC4,RBM14,
FEN1,GINS1,GLI2,DNA2L,PRIM2,PTMSGTPBP,
GMNN, ORC6L,GINS2,MCM4
GO:0000087 M phase of
mitotic cell cycle
33 200 5,57E-11 RAD21,RAN,RUVBL1,SMC4,BIRC5,CCNB2,
TXNL4A,CDC20,BUB1B,CDC6,ZWINTNDC80,
SMC2,CDC25A,KIF23,CENPF,AURKA,BRCA2,
KIF2C,BUB1,CDC2,NUDC,NCAPD3,NUSAP1,
CEP55,ASPM,CDC23,RCC2,CCNB1,CLASP1,
CIT,HELLS,ESPL1
GO:0006139 nucleobase, nucleoside,
nucleotide and nucleic acid metabolic process
184 3337 1,62E-09
GO:0005783 endoplasmic reticulum 61 731 1,01E-08
Genes on Chip = the amount of genes from each entity represented on the gene chip. Due to lack of space not all overexpressed genes are shown under Gene Symbols.
Some important genes and entities are discussed in the text.
doi:10.1371/journal.pone.0006554.t005
Table 6. A selection of down-regulated gene ontology (GO) entities and corresponding genes (Genes Down) in mesothelioma
versus parietal pleura.
GO term GenesDown Genes On Chip Corrected P-value Gene Symbols
GO:0007275 multicellular organismal development 129 1984 2,08E-05
GO:0048511 rhythmic process 10 61 0,0254 HLF,NR1D1,EGR2,EGR3,STAT5BCRY2,
ANG,PER3,TEF, PER1
GO:0030528 transcription regulator activity 93 1300 2,33E-05
GO:0045934 negative regulation of nucleobase, nucleoside,
nucleotide and nucleic acid metabolic process
28 290 0,0029
GO:0007154 cell communication 214 3326 1,80E-08
GO:0007165 signal transduction 197 3000 1,80E-08
GO:0007264 small GTPase mediated signal transduction 34 418 0,0080
GO:0007155 cell adhesion 59 664 1,45E-05
GO:0006952 defense response 49 500 1,45E-05
GO:0006954 inflammatory response 33 271 2,33E-05
GO:0003707 steroid hormone receptor activity 10 49 0,0069 NR4A1,NR1D1,NR3C2,NR5A2,
PGRMC2,
NR4A2,NR1D2,PPARA, THRB,NR3C1
doi:10.1371/journal.pone.0006554.t006
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pleura of case 2, 4 and 5 was much more alike than the parietal
pleura of 2, 4 and 5 that formed a separate cluster, showing that
tissues with a similar phenotype also share gene expression profile
characteristics[7]. We do not claim that the mesothelial cells of
these two membranes have different profiles, as these cells were
not microdissected and analysed separately, but the sum of gene
expression from all the cells give a picture of the activities of the
two membranes. A large proportion of the differentially overex-
pressed genes of the visceral pleura, 105/341 genes (Table 4) were
intrinsic to membrane, and the multiple functions of transporters
and channels as well as genes with unknown functions. Several
solute carrier family members (SLC) were down-regulated in the
parietal pleura, transporters of multidrug and toxic compounds
(SLC47A1), sodium-phosphate (SLC34A2), oligopeptide
(SLC15A2), amino acid (SLC6A14), glutamate (SLC1A1), sodi-
um/myo-inositol (SLC5A3) and glucose (SLC5A9) transporters.
Interestingly the proton exchange transporter gene NHE1
(SLC9A1) that is important for tumour metastasis was down-
regulated, as well as the sodium channel transporters SCN1A,
SCNN1B and SCN7A. AQP4, aquaporin 4 was down-regulated
as well, a gene important for water transport but also for cell
migration and metastasis. Of the transporter genes, only the zink
Figure 4. Protein expression of selected genes, AGGF1, TYMS and MSLN by immunohistochemistry. A–C–E: normal parietal pleura. B–
D–F: Biphasic mesothelioma with epithelial and sarcomarous components. A–B (x20): AGGF1(VG5Q) mRNA was overexpressed in mesothelioma, and
clearly protein was expressed (brown) in both tumour components (arrows). Strong expression in normal mesothelium was seen (arrow) but the
majority of endothelial and other pleural cells were negative. C–D (x40): TYMS (Thymidylate synthase) mRNA was overexpressed, also on the protein
level (brown), mostly in the epithelial component (arrow) of tumour. Normal pleura was negative. E–F (x20): MSLN (Mesothelin) mRNA was not
differentially expressed, that could be explained by the intense protein expression not only in epithelial tumour cells, but also in normal mesothelial
and stromal cells.
doi:10.1371/journal.pone.0006554.g004
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transporter (SLC30A1/ZNT1) was overexpressed in the parietal
pleura, a gene that is overexpressed in the lung response to
cobalt[9]. The presence of alveolar cells in the visceral pleural
samples is clearly reflected as four of five genes encoding surfactant
proteins were overexpressed in the visceral samples (Table 4). The
microscopic emphysema seen in the visceral pleural samples could
influence the gene profile, but this is unlikely as adhesion genes as
claudins, integrins and laminins were highly overexpressed,
reflecting the physiological phenotype of the visceral pleura
(Table 4)[10]Among the few genes over-expressed in parietal
pleura were PCOLCE and PCOLCE2, encoding procollagen
proteinase enhancers, important in formation of normal collagen
fibrils, and thus show that the expression represents collagen-rich
pleural tissue[11]. Parietal pleura has lymphoid tissue (Kampme-
ier’s foci) and is highly active in both production and transport of
pleural fluid[10], but these were not detected histologically and not
translated to gene expression. One explanation may be that these
foci are predominantly found in the basal parts of pleura, and our
samples were from more cranial areas. There are no obvious
explanations why signal transducer activity, multicellular organ-
ismal development and leukocyte trans-endothelial migration
genes are down-regulated in parietal pleura. These features were
similar to what was found in mesothelioma versus parietal pleura.
As an example, ITGA2 (integrin alpha 2) was downregulated in
parietal pleura, a membrane adhesion protein which polymor-
phisms are associated to breast and prostate cancer[12,13]. One
could speculate if some of these expression patterns represent a
transforming susceptibility profile of the parietal pleura. However,
due to the abovementioned uncertainties, the small number of
visceral samples and the fact that the parietal pleura is the
principal site of mesothelioma, in all further comparisons with
tumour the parietal pleura was used.
Mesothelioma versus parietal pleura
Importantly there were more down-regulated than overex-
pressed genes in tumour versus parietal tissue corresponding with
the recent findings of more chromosomal losses than gains in
mesothelioma[5]. Analyzing the data within the KEGG PATH-
WAYS and GO revealed several important pathways and
functions reflecting the aggressive and resistant phenotype of
mesothelioma and some of the novel and most interesting findings
will be highlighted below.
Nucleotide metabolism
As an expression of rapidly dividing cells, polymerases for RNA
and DNA synthesis were overexpressed as well as genes of the
purine and pyrimidine metabolism, but strikingly this was confined
to genes of the so-called ‘‘salvage pathways’’, where nucleobases
are recycled rather than synthesized de novo[14,15](Fig. 5).
TYMS was overexpressed, encoding thymidylate synthase, part of
the ‘‘salvage pathway’’ in mammals and known as the target of the
antifolate drug pemetrexed that is active in mesothelioma. Its
overexpression may confer to chemotherapy resistance and poor
prognosis in other tumours, and recently TYMS has been
regarded as an oncogene[16]. DTYMK (deoxythymidylate
kinase), a key kinase for deoxythymidylate synthesis and involved
in 5-Fu resistance was overexpressed[17]. A novel finding was
PKM2 (pyruvate kinase muscle 2) overexpression. It is generally
overexpressed in malignant tumours and encodes a key enzyme
that regulate the ATP:ADP and GTP:GDP ratios in tumour cells
and pooling of phosphometabolites that is a prerequisite for
nucleotide biosynthesis. The tetrameric form of this protein is
cleaved by oncoproteins such as the HPV16 E7[18] and the dimer
is detected in serum and in the faeces of gastrointestinal cancer
patients serving as a tumour marker[19]. Importantly NME1 and
Figure 5. Schematic presentation of the results of differential expression of the purine and pyrimidine pathways in tumour versus
parietal pleura (P,0.05). Genes encoding proteins responsible for DNA and RNA synthesis and recycling of purines and pyrimidines are
overexpressed (red), while genes having the opposite or regulating role (green) are down-regulated. Genes encoding de novo synthesis of adenosine,
guanosine, thymidine, cytidine and uracil were not differentially expressed (not shown). This pattern may represent salvage pathways facilitating
tumour growth. Up: CTPS =CTP synthase, DTYMK=deoxythymidylate kinase, TYMS= thymidylate synthase, UCK2= uridine-cytidine kinase,
UMPS=uridine monophosphate synthase, POLR1A=polymerase (RNA) I polypeptide A, POLR3B; polymerase (RNA) III (DNA directed) polypeptide
B, NME=non-metastatic cells 1, NME2= non-metastatic cells 2, PKM2=pyruvate kinase, muscle, PRIM2A=primase, DNA, polypeptide 2,
PNPT1=polyribonucleotide nucleotidyltransferase 1, PCNA=proliferating cell nuclear antigen, RRM1= ribonucleotide reductase M1. Down:
ADCY4= adenylate cyclase 4, GUCY1A3=guanylate cyclase 1, soluble, alpha 3, PDE2A=phosphodiesterase 2A, cGMP-stimulated, PDE4A=pho-
sphodiesterase 4A, cAMP-specific, PDE5A=phosphodiesterase 5A, cGMP-specific, ENTPD3= ectonucleoside triphosphate diphosphohydrolase 3.
doi:10.1371/journal.pone.0006554.g005
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NME2 (non-metastatic cells 1 and 2), diphosphorylases that
transfer phosphate groups between di- and trinucleotides (Fig. 5)
were overexpressed. They are also associated to metastasis
suppression in many cancer types[20]. Mesothelioma has mainly
a non-metastatic growth pattern and overexpression of these genes
may contribute to this phenotype.
Genes involved in cell cycle function
It is known that cell cycle deregulation is a general feature of
malignancy. Overexpression of the cell cycle, replication and M-
phase genes reflect the importance of this also in mesothelioma
(Fig. 6 and 7, Table 5). Genes driving all the phases of the cell
cycle were significantly overexpressed (Fig. 6). No cyclins or cyclin
dependent kinases (CDKs) that drive the cell cycle were down-
regulated. Several of these genes are related to oncogenesis and/or
have been proposed as anti-cancer targets for other tumours
(Fig. 7) and some will be discussed here.
The overexpressed CDC6 encodes a protein essential for the
initiation of DNA replication but has recently been shown to
possess oncogenic properties by suppression of the INK4/
ARF[21]. During the transition from a growth-arrested to a
proliferative state transcription of mammalian Cdc6 is regulated
by E2F proteins. E2F1-8 is a family of transcription factors with
repressor or stimulator effect. E2F2 and E2F7 are overexpressed
where the first is shown to be an activator and considered as an
oncogene, overexpressed in large size and aggressive ovarian
cancers[22]. The E2F transcription factors can be blocked by the
tumour suppressor protein pRb encoded by RB1 that was
overexpressed. In contrast to other cancers RB1 is rarely mutated
in mesothelioma but its suppressor function is inhibited due to
inactivation by phosphorylation or by viruses as SV40[23] that
recently was linked to mesothelioma oncogenesis. CDKN2A
(cyclin-dependent kinase inhibitor 2A) encoding the p16ink4a that
inhibits pRb phosphorylation is almost always deleted in
mesothelioma[6], resulting in normal but non-functional pRB
expression, was not differentially expressed. We detected down-
regulation its alternative reading frame gene, CDKN2AIP
(CDKN2A interacting protein). CDKN2AIP activates the impor-
tant tumour suppressor p53[24], consequently its down-regulation
could as well be important for mesothelioma progression.
Essential for the initiation of eukaryotic genome replication are
the MCM (mini-chromosome maintenance protein) complex that
consist of MCM2-7, proteins possessing DNA helicase activity,
and may act as a DNA unwinding enzymes. GMNN (geminin)
regulate this complex and ensures genomic stability in cycling cells
by preventing firing (or activation) of new replication origins
before completion of a mitotic cycle, to ensure that DNA is
replicated only once per cell cycle. MCM2, 3 and 6 that were
overexpressed in our material (Table 5) are associated to poor
prognosis in lung cancer[25], astrocytoma[26] and craniopharyn-
geal carcinoma[27] respectively. MCM3 is overexpressed in
multiple malignancies, regarded a more sensitive tumour marker
than Ki67, and 90% of mice injected with MCM3 transfected cells
developed epithelial tumours within 6 weeks[28]. MCM4
combined with GMNN overexpression as found in our material,
is also predictive for metastasis and poor survival in melanoma,
documented in a large prospective microarray study[29]. Geminin
may become a treatment target, as suppression by apigenin
inhibited pancreatic cancer cell replication in vitro[30].
PRKCI (protein kinase C iota) is a serine- threonine kinase
involved in cell cycle regulation by controlling the key cell cycle
regulator CDK7[31] and both were overexpressed. PRKCI is also
considered as an oncogene activated by nicotine and a critical
gene in lung cancer development, conferring cell survival, drug
resistance, migration and invasion[32,33]. CDK7 encodes a
protein that is required for assembly of the Cdk1(cdc2)/cyclin
B1 complex and mitotic entry[34]. This protein is thought to serve
as a direct link between the regulation of transcription and the cell
cycle[35]. Inhibition of CDK7 by gambogic acid induced
irreversible arrest of G2/M phase in gastric cancer cells, and is
thus a putative treatment target[36]. CCNB1 encoding cyclin B1
and CDK1 encoding cdc2 were overexpressed, as in many cancer
types, both essential components of the cell cycle regulatory
machinery. Mesothelioma cells treated with alpha- interferon were
blocked in the G2/M phase and cyclin B1/cdc2 expression was
down-regulated[37]. Another gene encoding a protein essential for
Figure 6. Schematic presentation of some of the overexpressed genes related to their activity in the various phases of the cell cycle
(P,0.05). The M-phase genes are overrepresented.
doi:10.1371/journal.pone.0006554.g006
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cell cycle progression through the G2/M transition, CDC23/APC
subunit 8 was overepressed. This APC (anaphase-promoting
complex) catalyzes the formation of cyclin B-ubiquitin conjugate
that is responsible for the ubiquitin-mediated proteolysis of B-type
cyclins and is also associated to tumorigenesis[38]. CDC20 is
required to activate ubiquitin ligation by the APC and appears to
act as a regulatory protein interacting with several points in the cell
cycle, among them two microtubule-dependent processes, nuclear
movement prior to anaphase and chromosome separation[39].
ORC6L is also overexpressed and is an essential gene that
coordinates chromosome replication and segregation with cytoki-
nesis and is overexpressed in colorectal cancer versus normal colon
tissues[40]. ESPL1 (separase) is crucial in separating the sister
chromatids at the moment of anaphase, and has also been
proposed as a drug target in cancer[41].
Recently in a genome-wide study of localised melanomas that
did or did not metastasize within four years, DNA replication
genes were highly overexpressed in the metastatic group. In our
material 10 genes out of their 35 were overexpressed (GMNN,
CDC6, CENPF, MCM3, MCM6, ORC6L, PCNA, PTTG1,
RFC4 and RFC5) and several other negative prognostic genes
were common with our study (BIRC5/survivin, BUB1, CCNB1,
CDC2, CENPA and MCM4)[29,42], rendering the replicative
system very important for future target development.
Circadian rhythms
Circadian rhythm genes have recently been related to
replication, damage responses and carcinogenesis and may play
a master role in cell division[43]. We found central circadian clock
genes differentially expressed (Table 6 and Fig. 8). The negative
regulators of the cell cycle PER (period) and CRY (cryptochrome)
genes, and their protein expression are downregulated in breast
and lung cancer tissue when compared with matched normal
tissue, as was found here, and methylation rather than mutation of
these genes confer to this phenotype [44,45,46]. Cellular
experiments have shown that their down-regulation confer
resistance against apoptosis. NR1D1 and NR1D2 encode RevErb
alpha and RevErb beta, two other negative regulators of the
Figure 7. Differentially overexpressed genes in tumour (red boxes) depicted in the Cell Cycle map from KEGG PATHWAYS
(Kanehisa et al., 2008) (P,0.05). 21 of 21 cell cycle genes were overexpressed in mesothelioma versus normal parietal pleura tissue. Potential
targets for anti-tumour treatment described in the litterature are marked (see text). Abbreviations: CDK7= cyclin-dependent kinase 7,
CHEK1= checkpoint homolog, E2F2 = E2F transcription factor 2, ORC6L=origin recognition complex, subunit 6 like, MCM2-3-4-6 =minichromosome
maintenance complex component 2-3-4-6, PCNA=proliferating cell nuclear antigen, RB1 = retinoblastoma, BUB1=budding uninhibited by
benzimidazoles 1 homolog, BUB1B= BUB1 beta, CDC7= cell division cycle 7 homolog, APC/C=CDC23, cell division cycle 23 homolog, anaphase-
promoting complex subunit 8, CCNB1= cyclin B1, CCNB2= cyclin B2, ESPL1= extra spindle pole bodies homolog 1, CDC2/CDK1= cell division cycle 2,
G1 to S and G2 to M, CDC6= cell division cycle 6 homolog, CDC20= cell division cycle 20 homolog, CDC25A= cell division cycle 25 homolog A.
doi:10.1371/journal.pone.0006554.g007
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mammalian clock and repressors of transcription were downreg-
ulated as well, and their role in cancer is currently investigated[47]
Moreover, we found the positive regulators of circadian rhythms
and cell cycle ARNTL/BMAL1 (aryl hydrocarbon receptor
nuclear translocator-like) and its heterodimer NPAS2 (neuronal
PAS domain protein 2)[48] overexpressed. Importantly, circadian
BMAL1 expression was in tumour of a mouse model followed by
TYMS expression and combined overexpression correlated to low
response and worse survival on 5-Fu treatment[49]. We also found
concomitant BMAL1 and TYMS overexpression indicating that
this clock gene may also be an important driver of mesothelioma
progression. Conversely, BMAL1 knockout conferred cycloho-
sphamide sensitivity and CRY knockout conferred cyclophospha-
mide resistance, showing that circadian genes are important in
drug resistance as well[50]. High mRNA levels in breast cancer of
the positive regulator TIMELESS has been significantly associated
with shorter relapse-free survival and recently been regarded as a
promising marker of tamoxifen resistance in women with estrogen
receptor alpha-positive breast tumors[51]. TIMELESS was also
overexpressed in the mesothelioma samples. The significant
overexpression of positive clock genes with concomitant down-
regulation of their negative counterparts seen here may be one of
the basic regulator mechanisms of mesothelioma cell division, and
thus in theory be an important pathway to target.
Apoptosis
Apoptotic pathways and genes therein were mainly down-
regulated in contrast to anti-apoptotic genes which were
overexpressed (Fig. 3). Genes encoding proteins activating the
anti-apoptotic NFkB (nuclear factor kappa beta) pathway were
overexpressed, among them IL1RAP (interleukin 1 related
accessory protein)[52] and PRKCA (protein kinase C alpha).
PRKCA is also overexpressed in glioma and small-cell lung cancer
and involved in several pathways of signal transduction, cellular
communication and immune system, among them the VEGF and
the ErbB signalling pathway[53].
AURKA (Aurora kinase A) was overexpressed, and in
mammalian cells overexpression leads to centrosome amplifica-
tion, genetic instability and transformation, as well as cisplatin
resistance. Its activation of the NFkB pathway has been proposed
as an important mechanism[54]. AURKA is overexpressed in
several cancers, and has been associated with shorter survival in
mesotheliomas[55]. Small molecule inhibitors of AURKA are
currently in phase II trials[56]. The important inhibitor of
apoptosis BIRC5/survivin that confers drug resistance and
tumour aggressiveness was also overexpressed, and discussed in
[7].
Angiogenesis
Angiogenesis is important for tumour progression and survival
[57], and antiangiogenic therapies targeting the VEGF and
VEGFR have been developed. VEGF protein is highly expressed
in mesothelioma [58], but the mRNA was not differentially
expressed here. As the relative proportion of vessels and
endothelial cells was much higher in the parietal samples than in
the tumor samples one could expect that there was some
Figure 8. Circadian rhythm genes differentially expressed in tumour shown with KEGG PATHWAYS (modified from Kanehisa et al.,
2008) (P,0.05). CRY2, PER1, PER3 and NR1D1/Rev-Erb alpha that function as negative regulators of transcription are down-regulated (green) whereas
both genes encoding the active transcriptional heterodimeric complex Bmal1(ARNTL):Npas2 (NPAS2) are overexpressed in mesothelioma versus normal
parietal pleura. Damaged circadian rhythms may be a key to the continuous replicative force in tumour cells, and thus possible treatment targets.
doi:10.1371/journal.pone.0006554.g008
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overexpression of angiogenetic genes in the normal tissue due to a
mass effect (Table 3). On the contrary there were very few genes
differentially expressed, of the 25 genes associated to angiogenesis,
GO:0001525, two of these genes were downregulated, namely
ANG (angiogenin) and the PLXDC1 (plexin-domain containing
protein 1). One gene was overexpressed in tumour, the AGGF1, a
recently discovered potent angiogenic [59]. VG5Q, the protein
encoded by this gene was overexpressed in .75% of tumour cells,
also the sarcomatoid component, as well as the endothelium of
pathologic vessels (Fig. 4 A–B). We have recently proposed this
pro-angiogenic protein as a target for mesothelioma treatment[7]
DNA repair and proteasome genes
DNA repair overexpression has recently been implicated in
primary tumours with subsequent high metastatic potential, e.g.
melanoma[42], and proteasome function interacts closely with
some repair mechanisms [60,61](Table 5). These repair systems
have not been related to mesothelioma previously, and their
possible implications for the extreme chemo- and radio-resistance
of mesothelioma is discussed further in our recent paper[7].
Cytokine-cytokine receptor interaction
Malignant tumours are generally known to express factors that
modulate their environment, e.g. growth and pro-angiogenic
factors, but are generally not responsive to normal control
mechanisms of the microenvironment. Interestingly cytokine-
cytokine receptor interaction pathways were severely altered by
down-regulation of 19/21 genes in KEGG PATHWAYS (not
shown), 197 genes of signal transduction and 33 out of 271
inflammatory genes (Table 6). The downregulated immune related
genes belonged to the family of chemoattractants i.e, chemokines
or growth factors i.e cytokines. Among those were several
interleukin receptors and ligands (IL15, IL11RA, IL3RA and
CSF2RB), the TGF-b- family receptor TGFBR2, and chemokine
ligands (CXC and CC subfamily, TNF, TFSF14/LIGHT and
BMP2). These are involved in inflammatory responses, chemotaxis
of monocytes, activation of natural killer cells, but also in cancer
suppression. Anomaly of these functions may be important for
tumour progression. Loss of the tumour suppressor TGFBR2
expression is seen in many cancers with microsatellite instability
and deleted in large-cell lung carcinoma[62]. Interestingly, array
analysis showed that estrogen suppresses TGFBR2 gene in
estrogen sensitive tumours[63], that could indicate a role of
estrogen in mesothelioma as well. Leukocyte transendothelial
migration genes were also downregulated, as discussed in our
recent paper[7]. Only two immune genes were upregulated in the
mesothelioma, one from the TGF-b family INHBE and one from
the IL-1 receptor family the IL-1 receptor antagonistic peptide
(IL1RAP). Interpretation of these findings could be that the
tumour, the stroma or both are less permissive to cytokine
activation and tumour suppressor activity due to down-regulation
of cytokine receptor and ligands, a genotype with defect cell-cell
communication facilitating progression and aggressive phenotype.
The results also suggest that mesotheliomas effectively shut down
attraction and activation of immune cells as an immune evasive
mechanism.
Susceptibility gene
Finally, mutation and dysfunction of the detoxifier GSTM1 is
related to high risk of head and neck and lung cancer in
smokers[64,65]. Down-regulation of GSTM1 is a novel finding in
mesothelioma, and its role in mesothelioma susceptibility should
be evaluated.
Study design and relevance of the samples
The study design as a whole was developed to avoid caveats of
microarray analysis of complex tissues. Since initiaton and
progression to a clinically detected malignant mesothelioma takes
20–60 years there are several unknown steps. We believe that our
included control patients (relatively young, healthy and not
exposed to asbestos) facilitated a true differential expression
between malignant and healthy tissue. Lack of appropriate control
samples in earlier studies may have been one reason for
incongruent results[66,67,68,69,70,71,72,73]. In spite of few cases
and controls, the differential gene expression detected was highly
significant.
The list of differentially expressed genes are based on a test that
the average expression level is up or downregulated, however for
as many as 519 of the reported upregulated genes and 542 of the
downregulated there is no overlap in gene expression levels
between the tumour and reference material. A large number of the
genes that are found as differentially expressed represent pathways
and biological processes widely known differentially regulated in
cancer. The procedure to identify the genes takes both magnitude
of change (fold change) and variability within the groups into
account, and the p - values are corrected for multiple testing
making it very likely that the reported genes are representative of
changes even if the number of samples is low.
Some overexpressed genes were confirmed by immunohisto-
chemistry and genes encoding proteins overexpressed in mesothe-
lioma were also overexpressed here (e.g. Ki67, Syndecan 1,
Survivin and Vitronectin). The genes FUT4 and ST6GALNAC3
coding for CD15 and Sialyl Transferase that are negative markers
of mesothelioma, were down-regulated[74]. Unexpectedly the
genes encoding the positive markers Calretinin, VEGFR and
Mesothelin were not differentially expressed. However, recent
studies showed that these are also expressed in normal mesothelial
cells[75,76,77].
Biopsies versus microdissected cells and cell lines
Mesothelioma arises in the pleura, but from which cell type?
The mesothelial cell has been taken for granted as the progeny of
mesothelioma, but recent studies showed that stem cells derived
from adipose tissue, circulating multipotent fibrocytes and adult
bone marrow-derived stem cells are able to transform to both
epithelial and mesenchymal cells[78,79,80]. Thus, the progenitor
cell could as well be a submesothelial fibrocyte/fibroblast or
another stem cell type. Epithelial mesothelioma can transform to
sarcomatoid phenotype[73], so one cannot argue that mesothelial
cells become epithelial mesothelioma and that the sarcomatous
type originate from fibrocytes/fibroblasts. Moreover, tumour
stroma gene expression may differ from normal stroma[81], and
its importance in tumour progression have recently been
acknowledged. As a systems biology approach, profiling of
tumour/stroma versus normal tissue/stroma may thus give
important information on the interplay between cells in the
microenvironment that would never be detected if only microdis-
sected cells or cell lines were examined. Cultured cells also have
the drawback of expressing other genes than malignant cells in
situ, even changing expression according to number of passag-
es[82] that further complicate the comparison.
Documentation of cell types and relative amount of each type
by visual inspection of two-dimensional slides of adjacent tissue as
done here was feasible and easy, but utmost important as the
variability of cell content was high. For this reason we suggest that
by any technique used to obtain material for comparisons of DNA
or RNA from complex tissues, an evaluation of cell-types are
should be pursued. This is, to our knowledge, the first
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mesothelioma microarray study to report the clinical status,
histological description of cell types and an estimate of the
proportion of cell types in biopsies from cases and controls. Even
with a small number of samples with high variability in cell content
we could see a differential expression of the three complex systems
of cells, the tumour, the parietal and the visceral pleura.
Conclusion
In conclusion, we have demonstrated a significant differential
gene expression of mesothelioma, visceral and parietal pleura by
genome-wide profiling, based on tissue samples that contained all
the cell types normally seen. The highly malignant, resistant but
non-metastatic phenotype of pleural mesothelioma was reflected in
the present gene profile. Significant dysregulation of circadian
rhythm genes may be important in driving the malignant process.
An introvert and immunologically defensive genotype of meso-
thelioma was reflected by down-regulation of adhesion, cytokine
receptors, ligands and inflammatory response genes. Normal
parietal pleura showed downregulation of adhesion, solute
transporter and signal tranduction systems that could confer to
its susceptibility of transformation by asbestos. The results
underscore the vast complexity of mesothelioma biology and that
large-scale methods are necessary to reveal new functional
pathological aspects, finally aiming at target discovery.
Methods
Ethics statement
The study protocol was approved by the Regional Committee
of Research Ethics of Central Norway, the Health Departement
and the Norwegian Social Science Data Service. Informed consent
was obtained from all participants.
Mesothelioma and control patients
Mesothelioma patients diagnosed between 2003–2005 were
included. They were all subjected to a clinical examination and
answered a patient history questionnaire. Diagnostic biopsies and
material for gene expression were taken from adjacent locations
with needle by Computer Tomography and/or ultrasound
guidance. Diagnostic samples were formalin-fixed and paraffin-
embedded. Material for gene expression analysis was snap-frozen
in liquid nitrogen within two minutes. Biopsies of morphologically
normal pleura were obtained from persons who underwent Video-
Assisted Thoracoscopy (VATS) for recurrent pneumothorax, after
obtaining patient history and informed consent. Parietal pleura
that was stripped from the thoracic wall and visceral pleura
dissected from the wedge-resections of the lung, were snap-frozen
in liquid nitrogen within two minutes. Mesothelioma diagnosis was
carried out by senior pathologists and re-examined by H. Sandeck,
by including a standard panel of antibodies for immunohisto-
chemistry as well as supplementary antibodies were used.
Semi-quantitative histological description of adjacent
tissue biopsies
Biopsies from tumour and control adjacent to the biopsies for
microarray analysis, were examined histologically by H. Sandeck
to identify which cell types were included in each specimen and
also estimate the relative content of cells of each type (per cent of
total cell nuclei).
RNA-extraction
Methods used for RNA extraction were optimized to assure a
high quality RNA from the small needle biopsies of the tumours.
The final technique chosen was homogenization of frozen tissue
with MagnaLyser (Roche Diagnostics) following the manufactur-
er’s procedure 2650 sec, but using 700 mL lysis buffer (Roche
Diagnostics, Germany) as it gave higher RNA yield. The material
was then incubated for 30 min at room temperature, centrifuged
at 13000G for two minutes. 350 mL of the supernatant was used
for further RNA isolation. Manual isolation with High Pure RNA
Tissue Kit (Roche Diagnostics, Germany) according to the
producer’s protocol was performed. Quality control of RNA was
done with NanoDrop (Saveen & Werner AB, Sweden) and
Bioanalyzer (Agilent technologies, Inc. USA).
Microarray experiments
Microarray experiments were performed at the Norwegian
Microarray Consortium (NMC) at NTNU, Trondheim, Norway.
Gene expression analysis was performed by the Affymetrix
GeneChip system according to the manufacturer’s Eukaryote
Two-Cycle protocol, starting with 75 ng deep frozen total RNA.
Labelled cRNA was hybridized to the Affymetrix Human Genome
U133 Plus 2.0 GeneChip (Affymetrix, Santa Clara, CA, USA), of
38 500 genes and 47 000 trancripts, allowing genome-wide
expression on a single array. The GeneChips were scanned using
the GeneChip Scanner 3000 (Affymetrix). Quality controls were
assessed using the GCOS v1.4 software, according to the
manufacturer’s manual (Affymetrix). All experiments have been
submitted to ArrayExpress registered with accession number E-
MTAB-47.
Microarray statistical analysis
The raw probe set intensities were normalised by robust multi
array average (RMA). Quality control was done of Benjamini and
Hochberg[83,84] and genes with corrected P-values smaller than
0.05 were taken as significant. The lists of significant genes were
tested for overrepresentation in KEGG PATHWAYS (Kyoto
Encyclopedia of Genes and Genomes)[53], and GO (gene
ontology) terms[85] using Fishers exact test. The distribution of
the gene expression pattern in significant pathways was visualised
in the loading space of a bridge-partial least squares regression
(PLS) model[86].
Validation
Cell specific expression of proteins encoded by six selected
genes, were validated by immunohistochemistry (respective gene
symbols in brackets). The following antibodies were tested on fixed
tissues adjacent to samples subjected to microarray. Thymidylate
Synthase (TYMS ) (Millipore, USA) dilution 1:50, VG5Q
(AGGF1) (Abcam, Cambridge UK) dilution 1:500, Chk1(CHE-
K1)(Epitomics, California, USA), dilution 1:10, overnight incuba-
tion at 24uC, NQO1 (NQO1) (Zymed Laboratories, Carlsbad,
CA, USA) dilution 1:50, RAD21 (RAD21) (Abcam, Cambridge
UK) dilution 1:500 and mesothelin (MSLN)(Novocastra Labora-
tories, Newcastle, UK) dilution 1:10, overnight incubation at
24uC. Selected positive and negative controls were included for all
antibodies.
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